SARCOMAS: Edited by Jonathan C. TrentPigmented villonodular synovitis therapy with MSCF-1 inhibitorsTemple, H. ThomasAuthor Information Department of Orthopaedic Surgery and the University of Miami Tissue Bank, University of Miami Miller School of Medicine, Miami, Florida, USA Correspondence to H. Thomas Temple, MD, Professor, Orthopaedic Surgery and Pathology, Vice Chairman, Department of Orthopaedic Surgery, University of Miami Miller School of Medicine, 1951 NW 7th Avenue, Suite 200, Miami, FL 33136, USA. Tel: +1 305 689 1432; e-mail: [email protected] Current Opinion in Oncology: July 2012 - Volume 24 - Issue 4 - p 404-408 doi: 10.1097/CCO.0b013e328354c16b Buy Metrics Abstract Purpose of review Giant cell tumor of tendon sheath and pigmented villonodular synovitis are synovial-based diseases that are generally treated by surgery. For aggressive and recurrent tumors, treatment alternatives are needed. This review explores a targeted therapeutic strategy. Recent findings Imatinib, a tyrosine kinase inhibitor, blocks expression of colony stimulating factor 1 (CSF1) by a small subpopulation of tumor cells that recruit CSF1-bearing nonneoplastic cells. Limited clinical data support the efficacy and side effect profile of imatinib in stabilizing disease in most patients. Summary Imatinib along with other such inhibitors and monoclonal antibodies to CSF1R are putative drugs that may play an important role in the treatment of these tumors. © 2012 Lippincott Williams & Wilkins, Inc.